Infectious disease
According to a BioPharma Dive report, since March, more than 100 biopharma companies announced their clinical trials were disrupted in some way because of the pandemic.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 19, 2020.
A new study published on Wednesday in the journal Nano Letters showed that cellular nanosponges may be able to inhibit SARS-CoV-2 infectivity within the body, ultimately neutralizing the virus.
The company announced it planned to soon start enrolling an open-label, single-arm Phase II/III clinical trial of remdesivir in about 50 pediatric patients with moderate-to-severe COVID-19, including newborns through adolescents.
The race toward a COVID-19 vaccine is focused around scientific development right now, but companies also need to be planning for manufacturing.
Numerous biopharma companies are testing or working to develop drugs and vaccines. But what is a bit unusual is the number of staffers at biotech and pharma companies and health care involved as participants in studies and clinical trials.
Researchers found that certain individuals who have never been exposed to COVID-19 appear to have “helper” T cells that are capable of recognizing and responding to the virus.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 17, 2020.
The warning came only a few hours after the FDA rescinded Emergency Use Authorization (EUA) for hydroxychloroquine and chloroquine for the treatment of COVID-19.
Low doses of a long-used steroid known as dexamethasone could be the solution to improving the chances of patients who become seriously ill from COVID-19 infection and require some kind of breathing assistance.
PRESS RELEASES